rovalpituzumab tesirine

Home
Ligands
rovalpituzumab tesirine

GtoPdb Ligand ID: 10561

Synonyms: Rova-T | SC0001-SCX

Comment: Rovalpituzumab tesirine is an antibody-drug conjugate (ADC) that was designed to exploit the expression of the NOTCH ligand DLL3 on certain tumours for anti-cancer efficacy [1]. It is a humanized anti-DLL3 monoclonal that is linked to a pyrrolobenzodiazepine dimer toxin called tesirine (or D6.5; PubChem CID 73672523). Once the ADC is internalized, its D6.5 payload is released and causes lethal DNA damage in the target cells.

No information available.

No information available.

Summary of Clinical Use
Rovalpituzumab tesirine was advanced to clinical trial, but its developer AbbVie, have discontinued its development. This decision was based on analysis of interim results from a Phase 3 study which indicated that rovalpituzumab tesirine demonstrated no survival benefit over placebo, as a first-line maintenance therapy for advanced small-cell lung cancer. Click here to link to ClinicalTrials.gov's full list of rovalpituzumab tesirine studies.

Summary of Clinical Use

Rovalpituzumab tesirine was advanced to clinical trial, but its developer AbbVie, have discontinued its development. This decision was based on analysis of interim results from a Phase 3 study which indicated that rovalpituzumab tesirine demonstrated no survival benefit over placebo, as a first-line maintenance therapy for advanced small-cell lung cancer. Click here to link to ClinicalTrials.gov's full list of rovalpituzumab tesirine studies.